Welcome to the Hill Group. We study the epidemiology of infections in patients with cancer, transplant recipients, CAR-T cell recipients, and other immunocompromised populations. Recent advances in molecular virology, drug development, and genetically modified T cell manufacturing provide new opportunities to improve patient outcomes through better diagnostic, prophylactic, and treatment strategies for infectious diseases. Dr. Joshua Hill's interest in this field stems from his experiences as a Transplant Infectious Diseases physician, where he witnesses the impact of infections in vulnerable patients.
Dr. Josh Hill will study how immunotherapy impacts patients’ ability to fight off bugs
Hutch News | January 2020